Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925976 | 0.97 | CYP2B6 (0.37) | CYP2B6HRH3TSHRTDP1NPC1 | |
| SCHEMBL11587102 | 0.97 | CYP2B6 (0.37) | CYP2B6HRH3TSHRTDP1NPC1 | |
| SCHEMBL18059326 | 0.94 | — | — | |
| SCHEMBL21121000 | 0.88 | HRH3 (0.38) | HRH3TSHRTDP1 | |
| SCHEMBL24419835 | 0.85 | HRH3 (0.33) | HRH3 | |
| SCHEMBL24702161 | 0.81 | POLB (0.36) | HRH3TSHR | |
| SCHEMBL18412487 | 0.80 | HRH3 (0.35) | HRH3TSHRTDP1 | |
| SCHEMBL7868108 | 0.79 | — | — | |
| SCHEMBL24179805 | 0.79 | CXCR4 (0.35) | HRH3TDP1 | |
| SCHEMBL24663779 | 0.79 | CYP2B6 (0.34) | CYP2B6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-9963447-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-08 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2265585-B1 | AMINE AND ETHER COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CYP2B6 2589/4885HRH3 634/4885TSHR 94/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | CYP2B6 2113/4885HRH3 1935/4885TSHR 1656/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | CYP2B6 2113/4885HRH3 1935/4885TSHR 1656/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | CYP2B6 2113/4885HRH3 1935/4885TSHR 1656/4885 |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | CYP2B6 3312/4885HRH3 2909/4885TSHR 1786/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | CYP2B6 618/4885HRH3 3194/4885TSHR 4207/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | CYP2B6 3108/4885HRH3 342/4885TSHR 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.